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MinigenomeComparative and mutational analysis of promoter regions of rinderpest virus was conducted. Minigenomic
RNAs harboring the genomic and antigenomic promoter of the lapinized virulent strain (Lv) or an attenuated
vaccine strain (RBOK) were constructed, and the expression of the reporter gene was examined. The
activities of the antigenomic promoters of these strains were similar, whereas the activity of the genomic
promoter (GP) of the RBOK strain was signiﬁcantly higher than that of the Lv strain, regardless of cell type
and the source of the N, P and L proteins. Increased replication (and/or encapsidation) activities were
observed in the minigenomes that contained RBOK GP. Mutational analysis revealed that the nucleotides
speciﬁc to the RBOK strain are responsible for the strong GP activity of the strain. It was also demonstrated
that other virulent strains of RPV (Kabete O, Saudi/81 and Kuwait 82/1) have weaker GPs than that of the
RBOK strain.
© 2009 Elsevier Inc. All rights reserved.Introduction
Adaptation of viruses to cell culture or in other hosts and
attenuation in the natural host are often coupled. The mechanism
underlying this phenomenon is only partially understood. Some
viruses are adapted to replicate in semi-permissive cells or hosts using
alternative receptors or cofactors, while others are adapted to grow at
elevated or reduced temperatures. Acquisition of such phenotypes
leads to attenuation in the original hosts. Comparative analyses using
viruses that are chimeric between the original (or virulent) strain and
the adapted (or attenuated) strain allow us to identify the gene or
genomic region responsible for the attenuated phenotype.
Rinderpest virus (RPV), which causes severe disease in cattle and
wild bovids, belongs to the Morbillivirus genus in the family Para-
myxoviridae. The terminal regions of the genomic RNAs of the
paramyxoviruses are highly conserved, and include elements for
encapsidation and viral RNA synthesis (Lamb and Parks, 2006). The
3′-proximal untranslated region is called the ‘genomic promoter’
(GP), and a 5′-proximal region is called the ‘antigenomic promoter’
(AGP). Viral RNA synthesis involves transcription and replication.
After entry of the virus into a cell, primary transcription is carried
out on the viral ribonucleoprotein (RNP) complex, which consists of
viral RNA and three viral proteins (N (nucleocapsid), P (phospho-)
and L (large) proteins), and leads to the synthesis of mRNAs forenter, The Institute of Medical
Minato-ku, Tokyo 108-8639,
ll rights reserved.individual proteins (transcription). When sufﬁcient viral proteins
have accumulated, viral RNA-dependent RNA polymerase (RdRp)
switches from the transcriptional mode to the replication mode,
leading to the synthesis of full-length antisense genomic RNA
which, in turn, is used as a template for synthesis of genomic RNA
(replication). A measles virus (MV) genome analog in which the
entire coding region for viral proteins was replaced by a single open
reading frame (ORF) of the chloramphenicol acetyl transferase
(CAT) reporter gene was able to undergo transcription, replication
and packaging to form infectious virus-like particles in the presence
of measles helper virus (Sidhu et al., 1995). This demonstrates that
the GP and AGP regions are sufﬁcient to direct transcription and
replication. The terminal 20 nucleotides (nt) or so of the GP and
AGP of nonsegmented negative-strand RNA viruses are highly
conserved, and mutations within these conserved regions have a
detrimental effect on replication (Fearns et al., 2002; Hoffman and
Banerjee, 2000; Mioulet et al., 2001; Peeples and Collins, 2000).
Furthermore, an internal motif consisting of three hexamers (5′-
GNNNNN-3′)3, which spans nt 79–96, has been identiﬁed, and has
proven to be essential for replication of sendai virus (SeV) (Tapparel
et al., 1998). It has also been reported that the internal motif
(GNNNAN)2(GNNNCN) of MV, at the same position, is important for
replication (Walpita, 2004).
The GP also contains the leader region, the function of which is not
fully understood. However, it has been suggested that the leader RNA
plays important roles in viral transcription and replication. In RPV, the
cellular La protein has been shown to interact with the leader RNA,
and overexpression of La protein increased viral replication/tran-
scription in a minireplicon assay (Raha et al., 2004). Recently, it has
been shown that the La protein shields the leader RNA of respiratory
170 C. Imai et al. / Virology 396 (2010) 169–177syncytial virus from recognition by RIG-I (Bitko et al., 2008).
Furthermore, the leader RNA interacted with the unphosphorylated
P protein of RPV, but not with the phosphorylated P protein (Raha etal., 2004). It should be noted that the phosphorylation status of the P
protein can also affect whether polymerase transcribes or replicates
the genome (Pattnaik et al., 1997).
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can be found in the pathogenicity of ﬁeld isolates, from those causing
essentially 100% mortality to others that induce barely detectable
clinical signs (Taylor, 1986; Wamwayi et al., 1995). Although the
molecular basis of this variation is unknown, it has been reported that
the promoter sequence is one of the determinants of the pathogenic-
ity of RPV (Banyard et al., 2005). An attenuating mutation has also
been found in the GP region of human parainﬂuenza virus type 2
(Nolan et al., 2007). It was also demonstrated that substitution of two
mutations within the leader region of an egg-passaged strain of SeV
for the original nucleotides observed in the parental virus restored the
virulence of the virus in mice by altering virus replication in a host-
dependent manner (Fujii et al., 2002). Therefore, mutations within
promoter sequencesmay also play an important role in the adaptation
of viruses to different hosts.
The RBOK strain of RPV is used as a vaccine in cattle, and is derived
from the virulent Kabete ‘O’ strain after multiple passages of the virus
in primary calf kidney cell culture (Plowright and Ferris, 1962). The L
strain of RPV is also derived from the Kabete ‘O’ strain but is a
lapinized vaccine strain obtained by continuous passage in rabbits
(Nakamura and Miyamoto, 1953). Both the RBOK and the L strain are
avirulent in cattle; however, rabbits infected with the L strain develop
severe clinical signs that are similar to those in cattle infected with
virulent RPV (Fukuda and Yamanouchi, 1976; Imaoka et al., 1988a,b;
Kobune et al., 1976a,b; Yamanouchi et al., 1974a,b). In contrast, the
RBOK strain does not cause illness in rabbits. The RPV Lv strain, which
is highly virulent in rabbits, was obtained by cloning virus from the
RPV L strain, and its reverse genetics system has been established
(Yoneda et al., 2002). In vivo experiments using chimeric viruses of
the RBOK and Lv strains of RPV have shown that the H protein of the
Lv strain confers infectivity in rabbits, while the P protein of the Lv
strain plays an important role in pathogenicity (Yoneda et al., 2002,
2004). However, a chimeric virus that possessed the P and H proteins
of the Lv strain was still less virulent than the parental Lv strain
(Yoneda et al., 2004). This indicates that other region(s) of the Lv
genome is also required for the RPV to be fully pathogenic in rabbits.
To investigate whether there are functional differences in the
promoter regions of these strains of RPV, we constructed mini-
genomes of RPV that contain a ﬁreﬂy luciferase gene ﬂanked by the
genomic and antigenomic promoters of RPV, and conducted compar-
ative and mutational analyses of these regions.
Results
The activity of the RBOK GP is stronger than that of the Lv GP regardless
of the source of the replication proteins in 293 cells
First, minigenomic RNAs, RR (GP and AGP from the RBOK strain),
LR (GP from the Lv strain and AGP from the RBOK strain), LL (GP and
AGP from the Lv strain) and RL (GP from the RBOK strain and AGP
from the Lv strain), and supporting plasmids expressing the N, P and L
proteins of the RBOK strain were co-transfected into 293 cells that had
been infected with the vTF7-3. Luciferase activities were measured 24
h after transfection to test whether there were any differences in
transcriptional efﬁciency between the cis-acting elements (GP and
AGP) of the RBOK and Lv strains. The minigenomes that contained the
GP of the RBOK strain, RR and RL, showed higher luciferase activities
than those containing the GP of the Lv strain, LR and LL (Fig. 1B, panel
a). The RR was approximately 20 times more active than the LR.Fig. 1. (A) Schematic representation of plasmids for chimeric minigenomes. The cDNAs con
inserted between the T7 promoter sequence and the ribozyme sequence of hepatitis delta v
minigenome plasmids by T7 RNA polymerase are negative-sense (genome-sense) and have p
sequences derived from the Lv strain. (B) Luciferase activities in cells transfected with ch
expressing N, P and L proteins of either the RBOK strain (a, c and d) or Lv strain (b) were co-t
vTF7-3 at an moi of 2, and luciferase activities were measured 24 h after transfection. RelatSimilarly, the RL had 9.6-fold higher activity than the LL. These results
suggest that the GP of the RBOK strain is stronger than that of the Lv
strain. There was also a little difference between the RR and RL, and
the LR and LL, indicating that there might be a slight difference in
activity of the AGP between the RBOK and Lv strains. However, the
effect of the AGP exchange is dependent on the GP sequence, i.e.,
homogeneous combinations of GP and AGP exhibited higher activity
than heterogeneous combinations. Therefore, we conclude that the
activity of the GP of the RBOK strain is much stronger than that of the
Lv strain, while the activities of the AGP of these strains are similar. In
these experiments, the N, P and L proteins that support transcription
and replication of the minigenomic RNA were derived from the RBOK
strain. Given that these strains have long and different histories of
adaptation, speciﬁcally numerous passages in semi-permissive cul-
tured cells for the RBOK strain and in rabbits for the Lv strain, co-
evolution of the cis-acting elements and the replication proteins
might have occurred. This may have been responsible for the
incompatibility of the GP of the Lv strain with the N, P and L proteins
of the RBOK strain. To examine this possibility, a series of supporting
plasmids of the Lv strain was constructed. The amount of the
luciferase produced by the RR construct with supporting plasmids of
the Lv strain (an average activity of 1.1×107 RLU) was similar to that
with supporting plasmids of the RBOK strain (an average activity of
1.4×107 RLU). The effect of GP exchange was less pronounced when
the N, P and L proteins of the Lv strain were used, but had the same
trend as the experiments using the N, P and L proteins of the RBOK
strain (Fig. 1B, panel b). Therefore, the GP activity of the RBOK strain
was stronger than that of the Lv strain regardless of the strain from
which the replication proteins were derived.
The activity of the RBOK GP is stronger than that of Lv GP in other cells
Both strains of RPV grow well in a marmoset B cell line, B95a. The
RBOK strain also grows in Vero cells and primary bovine kidney cells,
while the Lv strain does not. It is possible that each strain has become
adapted to replicate in speciﬁc cell types or species. To address this
issue, minigenomic RNAs, RR, LR, LL and RL, were co-transfected into
B95a (the marmoset B cell line) (Fig. 1B, panel c) and RK13 (a rabbit
kidney cell line) (Fig. 1B, panel d) with supporting plasmids of the
RBOK strain. The B95a cells were chosen as a representative of
lymphoid cells, to which RPV targets in the host, and RK13 cells were
chosen as a representative of rabbit cells, to examine the host-species
speciﬁcity. Although the effect of GP exchange in B95a cells was
somewhat less pronounced than that in 293 or RK13 cells, and
average luciferase activities produced by the RR construct in B95a and
RK13 cells (7.7×105 RLU and 5.8×106 RLU, respectively) were lower
than that in 293 cells (1.4×107 RLU), the results obtained in either cell
type were similar to those in the 293 cells. Therefore, it appears that
the activity of the RBOK GP is dominant irrespective of the origin of
the cells.
Effect of the GP sequence on translation of the downstream gene
The sequence from nt 56 to 107 of GP overlaps the 5′ UTR of the
ﬁrst gene of the genome (i.e., the N gene) (Fig. 2). In our minigenome
system, this region corresponds to the 5′ UTR of the luciferase gene.
The level of luciferase activity reﬂects the amount of luciferase
translated from its mRNA. It is generally considered that the sequence
of the 5′ UTR affects the translation efﬁciency and/or the stability oftaining luciferase ORF ﬂanked by the GP and AGP of the RBOK or Lv strain of RPV were
irus followed by two tandem copies of the T7 terminators. The RNAs synthesized from
recise 5′ and 3′ ends. Gray boxes: sequences derived from the RBOK strain. Black boxes:
imeric minigenomes. Minigenomic RNAs, RR, LR, LL and RL, and supporting plasmids
ransfected into 293 (a and b) B95a (c) or RK13 (d) cells that had been infected with the
ive values to the activity of RR (%) are shown.
Fig. 2. Geomic and antigenomic promoter sequences of RPV strains. Upper panel: alignment of GP sequences of ﬁve RPV strains. Lower panel: alignment of AGP sequences. Open box:
nucleotides characteristic of the RBOK strain.
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might affect the translation efﬁciency of the luciferase mRNA, the
difference in this sequence between the RBOK and Lv strains should
be taken into account. Therefore, plasmids producing synthetic
mRNAs within which the 5′ UTR of the N gene of the RBOK or Lv
was placed upstream of the luciferase gene were constructed. These
plasmids were transcribed in vitro in the presence of the m7G cap
analog, and the RNA was transfected into 293 cells. Both mRNAs
produced similar amounts of luciferase (9.5×106 RLU for RBOK N5′
UTR-Luc, 9.3×106 RLU for Lv N5′UTR-Luc; relative activities are
shown in Fig. 3), indicating that the effect of the exchange of the 5′
UTR of the N gene between the RBOK and Lv strains had little effect on
translation (and the stability of the mRNA). Similar results were
obtained with in vitro translation reactions using rabbit reticulocyte
lysate (data not shown). These results suggest that the differences in
the luciferase activity described above correspond to differences in
the amount of luciferase mRNA.
Effect of the GP sequence on synthesis of encapsidated antigenome
Given that GPs of mononegaviruses direct both replication and
transcription, it is of interest to know whether the strong GP activity
of the RBOK strain affects replication (and/or encapsidation),
transcription or both. To investigate the effect of the GP sequenceFig. 3. Comparison of the translation efﬁciencies of synthetic mRNAs harboring the 5′
UTR of the N gene of the RBOK or Lv strain. In vitro transcripts harboring the luciferase
gene downstream of the 5′ UTR of the N gene of either the RBOK or the Lv strain were
transfected into 293 cells, and luciferase activity was measured 24 h after transfection.
The value obtained from the RNA harboring the sequence of the RBOK strain was set to
100%.on replication (and/or encapsidation), newly synthesized encapsi-
dated antigenome produced in 293 cells by minigenomic RNAs were
evaluated by real-time RT-PCR. The lysates of the transfected cells
were treatedwithmicrococcal nuclease to digest luciferasemRNA and
cellular RNAs. The genomic RNA is encapsidated and thus resistant to
nuclease digestion. After nuclease digestion, the genomic RNA was
extracted and subjected to quantitative RT-PCR, by which the
amounts of the antigenome sense RNA were measured. The levels of
positive-sense genomes containing the RBOK GP, RR and RL were
higher than those containing the Lv GP, LR and LL (Fig. 4). The
amounts of the encapsidated antigenome by each construct correlated
well with the extents of the luciferase activity detected in 293 cells
(Fig. 1B, panel a). Therefore, it was suggested that stronger GP activity
of the RBOK strain was not due to the stronger transcription activity,
but mainly due to the stronger replication (and/or encapsidation)
activity of the RBOK GP.
Mutational analysis of GP
Fifteen of the 107 nt of GP differ between the RBOK and Lv strains
(Fig. 2). To investigate which nucleotide(s) are responsible for the
different GP activity of these strains, we conducted mutational
analysis of GP. First, we constructed mutant minigenomes in which
the nucleotides of the RBOK GP were mutated to those of the Lv GP.Fig. 4. Comparison of the encapsidated antigenome RNA synthesis. The minigenomic
RNAs were transfected into vTF7-3-infected 293 cells with supporting plasmids of the
RBOK stain. After 20-h incubation, the cells were lysed and treated with micrococcal
nuclease before RNA extraction. Quantitative RT-PCR was performed to speciﬁcally
amplify the positive-sense genomic RNA. Relative values to the amount produced by RR
(%) are shown.
Fig. 5.Mutational analysis of the RBOK GP. Nucleotides at indicated positions of pRR were substituted for those of the Lv GP. Transfection of the in vitro transcripts was carried out
with the RBOK-based supporting plasmids using 293 cells. Luciferase activities were measured 24 h after transfection. Relative activities to RR (%) are shown.
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P and L proteins of the RBOK strain. Any single mutation was not
sufﬁcient to reduce the GP activity to the level of the Lv GP (Fig. 5).
Among the mutated nucleotides, G90A and C95A mutations had
noticeable effects on GP activity (60.8% and 46.2% of the wild-type
(wt) level, respectively). The double mutant (G90A/C95A) showed
lower activity (25.8% of the wt level) than the single mutants, but the
activity was still higher than that of Lv GP. Triple and quadruple
mutations, including G90A and C95A mutations, did not further
reduce the activity signiﬁcantly. Several mutations (e.g., U26G andFig. 6.Mutational analysis of the Lv GP. Nucleotides at indicated positions of pLR were subs
with the RBOK-based supporting plasmids using 293 cells. Relative activities to RR (%) areC49U) within the leader region also reduced the GP activity, albeit
slightly. In contrast, C12U mutation enhanced the GP activity of the
RBOK strain, indicating that U at position 12 may be favorable for GP
activity. Although single mutations, except for G90A and C95A, had
little effect on GP activity, simultaneous mutations of nucleotides
between positions 1 and 50 (5/12/19/22/26/28/30/36/40/49) and
between 25 and 50 (26/28/30/36/40/49) exhibited 22.5% and 56.9%
of the wt activity, respectively (Fig. 5). The exchange of nucleotides
between 25 and 50 plus nt 90 and 95 (26/28/30/36/40/49/90/95)
further reduced the activity (to 8.3% of the wt level). Therefore,tituted for those of the RBOK GP. Transfection of the in vitro transcripts was carried out
shown.
Fig. 8. Effect of mutations on synthesis of encapsidated antigenome RNA. The
minigenomic RNAs with or without mutations at positions 5, 26, 90 and 95 of the
RBOK, Lv, Kabete O and Saudi/81 GPs were transfected into vTF7-3-infected 293 cells
with supporting plasmids of the RBOK stain. After 20-h incubation, the cells were lysed
and treated with micrococcal nuclease before RNA extraction. Quantitative RT-PCR was
performed to speciﬁcally amplify the positive-sense genomic RNA. Relative values to
the amount produced by RR (%) are shown.
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contributed to the reduced activity.
We also mutated nucleotides of the Lv GP that are different from
those of the RBOK strain to investigate which nucleotide changes
stimulate the activity of the Lv GP (Fig. 6). Single or combined
mutations were introduced into plasmid pLR (which contains Lv GP
and RBOK AGP), and the activity of each minigenome was analyzed in
the presence of the N, P and L proteins of the RBOK strain. Stimulation
of GP activity was apparent in A5G, G26U, A90G and A95C mutants.
Substitution of these nucleotides is characteristically observed in the
RBOK strain (Fig. 2). Further stimulation of GP activity was observed
in double (A5G/G26U and A90G/A95C), triple (A5G/A90G/A95C and
G26U/A90G/A95C) and quadruple (A5G/G26U/A90G/A95C)
mutants. Therefore, these RBOK-speciﬁc nucleotides are responsible
for the strong activity of the RBOK GP. The activity of the quadruple
mutant was higher than that of the minigenome harboring RBOK GP.
This result may be due to the C12U mutation observed in the Lv GP.
Given that it has been demonstrated that nucleotides at positions
5, 26, 90 and 95 are responsible for the strong GP activity of the RBOK
strain, and that these nucleotides in other strains of RPV are also
different from those of the RBOK strain (Fig. 2), it was speculated that
GP activities of other RPV strains are also weaker than that of the
RBOK strain. To test this possibility, the GP of the RBOK strain was
replaced by that of the Kabete O or Saudi/81 strains. The GP sequence
of another strain (the Kuwait 82/1 strain), which is available from
GenBank, is identical to that of the Saudi/81 strain (Fig. 2). The GP of
the Kabete O strain has a unique nucleotide at position 93, and that of
the Saudi/81 (and Kuwait 82/1) strain has unique nucleotides at
positions 24 and 31. Therefore, the effect of these nucleotides on GP
activity was also investigated. When the Kabete O- or Saudi/81-
speciﬁc mutations were introduced into the RBOKGP, a slight increase
in activity was observed, while there was little, if any, decrease in the
GP activity when the reciprocal mutations were introduced into the
Kabete O or Saudi/81 GP (Fig. 7). Introduction of A5G/G26U or A90G/
A95C mutations enhanced the activity of the GPs of these strains. The
A5G/G26U/A90G/A95C mutations of these GPs dramatically in-
creased the luciferase levels, suggesting the importance of the
RBOK-speciﬁc nucleotides in GP activity. The activity of the A5G/
G26U/A90G/A95C mutant of the Kabete O strain was higher than the
activity of the minigenome with the intact RBOK sequence, while that
of the Saudi/81 strain was comparable to that of the RBOK
minigenome. It should be noted that the nucleotide at position 12 ofFig. 7. Effect of the mutations observed in the Kabete O and Saudi/81 strains of RPV. Mutatio
has the AGP of the RBOK strain. Transfection of the in vitro transcripts was carried out with
shown.the Kabete O strain is U, as it is in the Lv strain, and that of the Saudi/
81 strain is C, as it is in the RBOK strain. Therefore, these results
support the hypothesis that U is preferred to C at position 12 of GP.
Effect of mutations at 5, 26, 90 and 95 on synthesis of
encapsidated antigenome
To test the effect of mutations at 5, 26, 90 and 95 on synthesis of
encapsidated antigenome, the amounts of antigenomes produced by
minigenomes harboring GP of the RBOK, Lv, Kabete O and Saudi/81
strains with or without mutations were analyzed by quantitative RT-
PCR after micrococcal nuclease treatment (Fig. 8). Substitution of
these positions of the RBOK GP for those seen in the other strains
decreased the synthesis of encapsidated antigenome, and substitu-
tions of these nucleotides of the other strains (Lv, Kabete O and Saudi/
81 strains) for those of the RBOK strains resulted in signiﬁcant
increase in the synthesis of encapsidated antigenomes to the level
comparable to or even higher than that of the intact RBOK GP. The
extent of the decrease and increase by mutations was similar to thatns were introduced into GPs of the RBOK, Kabete O and Saudi/81 strains. Each construct
the RBOK-based supporting plasmids using 293 cells. Relative activities to RR (%) are
175C. Imai et al. / Virology 396 (2010) 169–177observed in luciferase activity (Figs. 5–7), conﬁrming that the
nucleotide changes mainly contribute to replication and/or encapsi-
dation but not to transcription.
Discussion
In this study, comparative analysis using minigenomes was
performed to investigate the functional differences among cis-acting
elements of RPV strains. By using chimeric minigenomes that
harbored the GP and AGP of either the RBOK or the Lv strain, it was
demonstrated that the RBOK strain has stronger GP activity than the
Lv strain (Fig. 1B). This result was reproduced in other types of cell, of
lymphoid origin (B95a cells) and rabbit origin (RK13 cells) (Fig. 1B,
panel c and d); therefore, the GP of the Lv strain is inherently weaker
than that of the RBOK strain and this is not host cell-speciﬁc. The
weaker activity of the GP of the Lv was not caused by incompatibility
of the viral replication proteins, which consist of N, P and L proteins,
with the Lv GP (Fig. 1B, panel b). It has been reported that the cellular
La protein interacts with the leader region of RPV and enhances viral
RNA synthesis (Raha et al., 2004). Thus, it was suspected that
differences between the RBOK and Lv strains in the afﬁnity of the
leader to the La protein contributed to the difference in luciferase
activity. However, we could not ﬁnd such differences in an RNA gel-
shift assay using leader RNAs of the RBOK and Lv strains and
recombinant human La (data not shown). It was also demonstrated
that mRNAs of synthetic luciferase harboring the 5′ UTR of the N gene
of either the RBOK or the Lv strain produced similar amounts of
luciferase (Fig. 3). Therefore the possibility of the effect of the
mutations on translational efﬁciency of the downstream gene was
excluded.
Minigenomes that harbored the RBOK GP produced larger
amounts of encapsidated antigenomes than those harboring the Lv,
Kabete O or Saudi GP (Figs. 4 and 8). The extent of the differences in
replication products was almost parallel to the luciferase activities
that were conﬁrmed to reﬂect the amounts of the luciferase mRNA.
Therefore, this result suggests that the mutations mainly have an
effect on replication but not on transcription of RPV.
By conducting mutational analysis, we demonstrated that the
RBOK-speciﬁc nucleotides at positions 5, 26, 90 and 95 are responsible
for the strong activity of the RBOK GP. Substitution of these four
nucleotides of the RBOK strain for those of the other strains
dramatically reduced the activity (to approximately 20% of the wt
level in 293 cells) (Fig. 5). Conversely, substitutions of these four
nucleotides of the other strains for those of the RBOK strain enhanced
the GP activity to a level comparable to or even higher than that of the
RBOK strain. Furthermore, it was demonstrated that levels of
luciferase activity were parallel to the amounts of newly synthesized
encapsidated antigenomes (Fig. 8), supporting the hypothesis that the
mutations mainly have an effect on replication but not on transcrip-
tion of RPV. Interestingly, nucleotides at these positions of the AGP are
exactly the same as those of the RBOK GP (Fig. 2), indicating the
importance of these nucleotides in promoter activity. It should be
noted that vaccine strains of MV have U at position 26, like the RBOK
strain of RPV, whereasmost of the wtMV have A at this position. It has
been reported that substitution of U for A at position 26 decreased the
GP activity of MV to approximately 40% (Liu et al., 2006). It is possible
that the U at position 26 confers strong GP activity, and that viruses
having this sequence may be selected during the numerous passages
in cell culture that are used to obtain vaccine strains. Two nucleotide
substitutions, at positions 90 and 95, are located in the (GNNNAN)2
(GNNNCN) hexamer motif (Walpita, 2004). Using in vivo selection
experiments with randomized sequences within the hexamermotif of
MV, the original sequence of the vaccine strain was selected (Walpita,
2004), which indicates that the nucleotides within the hexamer motif
are under selective pressure, and the sequence of vaccine strain has an
advantage over any other sequence in terms of transcription/replication activity in cell culture. The work by Walpita (2004)
showed that the C to G substitution at position 95 within the
79(GNNNAN)2(GNNNCN)96 motif of theMVminigenome resulted in a
decrease in reporter gene activity to approximately 50%. In the RBOK
strain of RPV, this nucleotide is C, whichmatches the consensus, but in
other strains of RPV this position is A, which may not be a preferable
nucleotide at the 5th position of the third hexamer. The 90th
nucleotide is located at the 6th position of the second hexamer, and
the importance of this position has been less well demonstrated.
However, given the fact that substitution of the nucleotide at position
90 of the RBOK GP or the Lv GP for that of the Lv GP or the RBOK GP
affected GP activity, this position may also be important for the
replication/encapsidation activity of morbilliviruses. Other nucleotide
substitutions may also affect GP activity, although the effect of a single
nucleotide substitution is subtle. Accumulation of mutations within
the Lv GP is likely to be responsible for its low activity compared with
those of the Kabete O, Saudi/81 and Kuwait 82/1 strains, all of which
have the same nucleotides at positions 5, 26, 90 and 95.
It has been reported that A19G mutation of the RBOK GP resulted
in 90% reduction in reporter gene expression (Mioulet et al., 2001).
The GP of the RBOK has A at this position and that of the Lv has G at
this position. Therefore, we initially suspected that this was the reason
for the reduced GP activity of the Lv strain. However, contrary to
expectation, A19G mutation within the RBOK GP did not affect the GP
activity in this study; thus, our result is inconsistent with the results of
Mioulet et al. (2001). So far, there is no conclusive explanation to
account for this discrepancy. It is possibly attributable to differences in
the experimental design. It should be noted that the work by Mioulet
et al. was conducted with a positive strand minigenome expressing
the CAT gene and with a helper virus to supply the replication
proteins. Further study will be required to explain the discrepancy.
Intriguingly, a recent study demonstrated that a recombinant RPV
harboring the GP and AGP of the RBOK strain was attenuated in cattle,
even though the other regions of the genome, including all protein
ORFs, were derived from a highly virulent strain (Banyard et al.,
2005). In this study, it was demonstrated that the GPs of the RPV
strains that show virulence in the original host or the other animals
are weaker than that of the avirulent RBOK strain. Therefore, the
stronger GP activity of the RBOK strain may not be advantageous for
the virus with respect to the pathogenicity in the host. In the process
of adaptation within the semi-permissive cultured cells, high-output
viruses might be selected, and it is possible that pathogenicity is
neglected during that process. The question is, why should a virus
with high replication ability in cell culture be avirulent in vivo?
Further study using recombinant viruses may shed light on the
mechanism of cell culture adaptation and concomitant attenuation
in vivo.
Materials and methods
Cells and viruses
RK13 cells, a rabbit kidney epithelial cell line, and 293 cells were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM) (Sigma)
containing 10% fetal calf serum (FCS). B95a cells, a marmoset B cell
line (Kobune et al., 1990), were maintained in RPMI 1640 (Sigma)
containing 5% FCS. All media were supplemented with antibiotics,
benzylpenicillin (100 U/ml) and streptomycin (100 U/ml). Recom-
binant vaccinia virus (vTF7-3) expressing the bacteriophage T7 RNA
polymerase (Fuerst et al., 1986) was grown in HeLa cells.
Construction of plasmids
The GP (nt 1–107) and the AGP (nt 15744–15882) of RPV were
ampliﬁed by PCR using the following primers and pMDBRPV (Baron
and Barrett, 1997) or pMDB-Lv (Yoneda, 2003) as a template. R/GP-F:
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CTTTATGTTTTTGGGGTCTTCCATTTTAAAGAACCTGTGCC-3′, or L/GP-F:
5′-ACCAAACAAAGTTGGGTAGG-3′ (5′-phosphorylated) and L/GP-R:
5′-CTTTATGTTTTTGGGGTCTTCCATTTCAAAGAACCTTTGCC-3′ were
used for GP sequences. AGP-R: 5′-ACCAGACAAAGCTGGGGATAGA-3′
(5′-phosphorylated) and R/AGP-F: 5′-GAATGAGTGCACTCTAACCTATT-
TATTACACGGCGATCTTTCCGC-3′, or L/AGP-F: 5′-GAATTAATGCACTC-
TAACCTATTTATTACACGGCGATCTTTCCGC-3′ were used for the AGP
sequences. The coding region for ﬁreﬂy luciferase was ampliﬁed from
the pGL3-Basic vector (Promega) using the following primers with
PfuTurboDNA polymerase (Stratagene): Luci-F, 5′-CAGGATCCATGGAA-
GACGCCAAAAACATAAA-3′ Luci-R, 5′-CAGGGGATCCTTACACGGC-
GATCTTTCCGC-3′. Using these ampliﬁed fragments, overlap PCR was
performed to join the GP, the ORF of the luciferase gene, and the AGP.
The ampliﬁed products were then cloned between the EagI and BsmI
sites of pMDB1 (Baron and Barrett, 1997) and the sequences were
conﬁrmed. The resulting plasmids were designated pRR (GP and AGP of
the RBOK strain), pLR (GP of the Lv strain and AGP of the RBOK strain),
pLL (GP and AGP of the Lv strain), and pRL (GP of the RBOK strain and
AGP of the Lv strain), respectively (Fig. 1A).
Mutations were introduced into pRR or pLR by the overlap PCR
method using primers containing each mutation. The GP regions of
the Kabete O and Saudi/81 strains were cloned by introducing the
multiple mutations observed in each strain into pRR.
The ORF of the N, P and L genes derived from the Lv strain was
ampliﬁed by a standard PCR method using the following primers. P-F:
5′-GACTAGTATGGCAGAGGAGCAAGCCTACC-3′ (SpeI site underlined),
P-R: 5′-CTCGAGCTAGTTCTTTATAATTTTTGCC-3′ (XhoI site underlined),
N-F: 5′-GACTAGTATGGCTTCTCTCTTGAAGAGCTTG-3′ (SpeI site under-
lined), N-R: 5′-CTCGAGTTAGCTTAGCTGAGGAGATCCTTGTCG-3′ (XhoI
site underlined), L-F: 5′-ATGCGGCCGCCATGGACTCCCTCTCAGTCAA-3′
(NcoI site underlined), and L-R: 5′-GTTTAGCGGCCGCTCACTCTTGAAT-
TAATGCACT-3′ (NotI site underlined). The PCR fragments were cloned
into the pCR2.1-TOPO vector (Invitrogen) and the sequences were
conﬁrmed. The ORF of each gene was then introduced into pBluescript
KS(+) (Stratagene) for the N and P genes, and pGEM5zf(+) (Promega)
for the L gene by digestion with the respective restriction enzymes. The
resulting plasmids were designated pKS-NL, pKS-PL and pGEM-LL,
respectively.
Plasmid pTNT-Luc, which harbors the luciferase ORF, was
constructed as follows. The ORF of the luciferase gene was ampliﬁed
by PCR using the primers, 5′-GCGGTCGACGCCATGGAAGACGC-
CAAAAACATAAAG-3′ (SalI site underlined) and 5′-GCGCGGCCGCTA-
CACGGCGATCTTTCCGCC-3′ (NotI site underlined). The ampliﬁed
products were digested with SalI and NotI and inserted between the
same restriction sites of the pTNT vector (Promega).
To construct plasmids for comparison of the translation efﬁciency,
the 5′ UTR of the N gene and a part of the luciferase gene were
ampliﬁed using pRR or pLR as a template and the following primers:
T7-N5′UTR-F, 5′-GAAGATCTAATACGACTCACTATAGAGGATTCAA-
GATCCTATCGAC-3′ (BglII site underlined); and Luc-Aﬂ-R, 5′-GATGT-
GACGAACGTGTACATC-3′ (AﬂIII site underlined). The forward primer
contains the T7 promoter sequence. The ampliﬁed fragments were
digested by BglII and AﬂIII, and inserted between the BglII and AﬂIII
sites of pTNT-Luc. The resulting plasmids, which contained the 5′ UTR
of the N gene of the RBOK or Lv strain, were designated pTNT-R-N5′-
Luc and pTNT-L-N5′-Luc, respectively.
In vitro transcription
All plasmid DNAs were puriﬁed using a QIAGEN Plasmid Midi Kit
or Genopure Plasmid Midi Kit (Roche). In vitro transcription of
minigenomes was performed with the T7 RiboMAX Express Large
Scale RNA production system (Promega) according to the manufac-
turer's instructions. The reaction mixtures were treated with RNase-
free DNase, and RNAs were puriﬁed on MicroSpin G25 columns (GEHealthcare), followed by phenol–chloroform extraction and ethanol
precipitation. The RNA pellets were dissolved in RNase-free water,
aliquoted and stored at−80 °C. The in vitro transcription of pTNT-R-
N5′-Luc and pTNT-L-N5′-Luc was carried out using a RiboMAX Large
Scale RNA Production System-T7 (Promega) in the presence of Ribo
m7G Cap Analog (Promega) according to the manufacturer's recom-
mendations. Puriﬁcation of the transcripts was performed as
described above.
Transfection and luciferase assay
Transfection was performed on 293, RK13 and B95a cells. Cells
were prepared in 24-well plates at a concentration of 2×105 cells per
well 1 day before transfection. The cells were infected with vTF7-3
diluted in Opti-MEM I (Invitrogen) at a multiplicity of infection (moi)
of 2 plaque forming unit (PFU)/cell for 1 h at 37 °C in a volume of
250 μl. After the inoculum had been removed, 0.25 μg RNA and a
mixture of supporting plasmids, which contained 0.25 μg of pKS-N
(Baron and Barrett, 1997) or pKS-NL, 0.25 μg of pKS-P (Baron and
Barrett, 1997) or pKS-PL, and 25 ng of pGEM-L (Baron and Barrett,
1997) or pGEM-LL, were transfected using 3 μl of DMRIE-C (Invitro-
gen) as a transfection reagent. After 4-h incubation at 37 °C, the
medium was discarded, and growth medium containing 40 μg/ml of
cytosine β-D-arabino-furanoside (AraC) (Sigma) and 50 μg/ml of
rifampicin (Sigma) was added to each well. The cells were incubated
for 20 h at 37 °C. For assay of translational activity using in vitro
transcripts from pTNT-R-N5′UTR-Luc and pTNT-L-N5′UTR-Luc, 293
cells were transfectedwith the RNAs using TransMessenger (QIAGEN)
according to themanufacturer's instructions, and incubated for 24 h at
37 °C. The cells were lysed in 100 μl of Passive lysis buffer (Promega).
The lysates were incubated for 15 min at 20 °C, followed by
centrifugation at 15,000 rpm for 3 min in a microcentrifuge. The
resulting supernatants were subjected to the luciferase assay. The
luciferase activities of cell lysates were measured using Picagene
(Toyo Ink) as a substrate, according to the manufacturer's instruc-
tions. All experiments were performed at least in triplicate.
Quantitative reverse transcription (RT)-PCR
As described above, 293 cells were transfected with the mini-
genome. At 20 h post-transfection, the cells were lysed in 125 μl of
lysis buffer containing 10 mM Tris–HCl (pH 7.5), 10 mM NaCl, 5 mM
MgCl2, 2 mM CaCl2, 1% Triton X, 0.5% sodium DOC, protease inhibitor
cocktail (Roche: without EDTA), 100 U/ml of DNaseI (Takara) and
100 U/ml of micrococcal nuclease (Roche). The lysate was incubated
for 1 h at 37 °C to degrade the non-encapsidated RNAs. Encapsidated
RNAswere subsequently extracted using Trizol LS (Invitrogen). Before
the ethanol precipitation step, 1 μg of yeast tRNA was added to each
sample as a carrier RNA. For reverse transcription, half of the extracted
RNA and a primer (5′-CCAGACAAAGCTGGGGATAG-3′) that is speciﬁc
for positive-sense RNA were used. The RT reactions were performed
using PrimeScript (Takara), according to the manufacturer's
instructions.
The PCR was performed using SYBR premix Ex Taq (Takara)
according to the manufacturer's recommendations. A primer pair,
lucF: 5′-GAGGTTCCATCTGCCAGGTA-3′ and lucR: 5′-CCGGTATCCA-
GATCCACAAC-3′, was used to quantify the positive-sense encapsi-
dated RNAs. Data were collected and analyzed using the ABI PRISM
7900HT Fast Real-Time PCR System.
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